Comparative Pharmacology
Head-to-head clinical analysis: GLATIRAMER ACETATE versus TERIFLUNOMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GLATIRAMER ACETATE versus TERIFLUNOMIDE.
GLATIRAMER ACETATE vs TERIFLUNOMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glatiramer acetate is a mixture of synthetic polypeptides composed of four amino acids (L-glutamic acid, L-lysine, L-alanine, and L-tyrosine). Its mechanism is not fully understood but is thought to modulate the immune system by inducing antigen-specific suppressor T cells, shifting the cytokine profile from pro-inflammatory (Th1) to anti-inflammatory (Th2), and promoting neuroprotection through increased brain-derived neurotrophic factor (BDNF) production.
Teriflunomide inhibits dihydroorotate dehydrogenase, a key enzyme in de novo pyrimidine synthesis, thereby reducing proliferation of activated T and B lymphocytes.
20 mg subcutaneously once daily for relapsing forms of multiple sclerosis.
7 mg orally once daily with or without food.
None Documented
None Documented
Clinical Note
moderateTeriflunomide + Gatifloxacin
"Teriflunomide may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateTeriflunomide + Rosoxacin
"Teriflunomide may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateTeriflunomide + Trovafloxacin
"Teriflunomide may increase the neuroexcitatory activities of Trovafloxacin."
Clinical Note
moderateTeriflunomide + Nalidixic acid
Terminal half-life is approximately 1-2 hours for the parent compound; however, clinical effects persist for days to weeks due to immunological mechanisms (e.g., antigen-specific T-cell modulation).
Terminal half-life approximately 18-19 days (range 10-30 days) due to enterohepatic recirculation. Clinical context: Requires prolonged elimination (up to 2 years to reach undetectable levels) due to slow clearance; accelerated elimination with cholestyramine or activated charcoal may be needed for toxicity.
Primarily renal excretion of intact glatiramer acetate and its metabolites; minimal biliary/fecal elimination. Exact percentages not established due to extensive metabolism.
Primarily biliary/fecal (approximately 60% unchanged drug and metabolites in feces, 23% in urine). Renal elimination of unchanged drug is minimal (<0.5%). Enterohepatic recycling contributes to long half-life.
Category A/B
Category C
Immunomodulator
Immunomodulator
"Teriflunomide may increase the neuroexcitatory activities of Nalidixic acid."